

# Nephrotic syndrome - Pipeline Insight, 2021

<https://marketpublishers.com/r/N26B8B72F56BEN.html>

Date: September 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: N26B8B72F56BEN

## Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Nephrotic syndrome - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Nephrotic syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Nephrotic syndrome Understanding

#### Nephrotic syndrome: Overview

Nephrotic syndrome is a group of symptoms that show your kidneys are not working as well as they should. These symptoms include too much protein in your urine, not enough protein in your blood, too much fat or cholesterol in your blood, and swelling. Anyone can get nephrotic syndrome but it is slightly more common in men than in women. In children, it happens most often between the ages of 2 and 6. The most common primary cause of nephrotic syndrome in adults is a disease called focal segmental glomerulosclerosis (FSGS). The only way to know for sure whether you have FSGS is to get a kidney biopsy. Even when treated, most people with FSGS will eventually develop kidney failure and will need to start dialysis or have a kidney transplant to live. After transplant, there is still a chance that FSGS will return and you

may lose your new kidney.

'Nephrotic syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nephrotic syndrome pipeline landscape is provided which includes the disease overview and Nephrotic syndrome treatment guidelines. The assessment part of the report embraces, in depth Nephrotic syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nephrotic syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

### Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Nephrotic syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Nephrotic syndrome.

### Nephrotic syndrome Emerging Drugs Chapters

This segment of the Nephrotic syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### Nephrotic syndrome Emerging Drugs

#### Belimumab: GlaxoSmithKline

Belimumab is a fully human monoclonal antibody that has been developed by GlaxoSmithKline/MedImmune. Currently, it is in Phase II stage of clinical trial evaluation to treat Nephrotic syndrome.

Further product details are provided in the report.

## Nephrotic syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Nephrotic syndrome drugs segregated based on following parameters that define the scope of the report, such as:

### Major Players in Nephrotic syndrome

There are approx. 3+ key companies which are developing the therapies for Nephrotic syndrome. The companies which have their Nephrotic syndrome drug candidates in the most advanced stage, i.e. phase II include, GlaxoSmithKline.

### Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Nephrotic syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nephrotic syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nephrotic syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nephrotic syndrome drugs.

## Nephrotic syndrome Report Insights

Nephrotic syndrome Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## Nephrotic syndrome Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Treatment Scenario and Emerging Therapies:

How many companies are developing Nephrotic syndrome drugs?

How many Nephrotic syndrome drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nephrotic syndrome?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Nephrotic syndrome therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Nephrotic syndrome and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

GlaxoSmithKline

Goldfinch Bio, Inc.

Travere Therapeutics, Inc.

Aurinia Pharmaceuticals

Bristol-Myers Squibb

ChemoCentryx

SynAct Pharma AB

## Key Products

Belimumab

GFB-887

RE-021

Voclosporin

Abatacept

AP1189



## Contents

- Introduction
- Executive Summary
- Nephrotic syndrome: Overview
  - Causes
  - Mechanism of Action
  - Signs and Symptoms
  - Diagnosis
  - Disease Management
- Pipeline Therapeutics
  - Comparative Analysis
- Therapeutic Assessment
  - Assessment by Product Type
  - Assessment by Stage and Product Type
  - Assessment by Route of Administration
  - Assessment by Stage and Route of Administration
  - Assessment by Molecule Type
  - Assessment by Stage and Molecule Type
- Nephrotic syndrome – DelveInsight's Analytical Perspective
- Mid Stage Products (Phase II)
  - Comparative Analysis
- Belimumab: GlaxoSmithKline
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.
- Early Stage Products (Phase I)
  - Comparative Analysis
- Drug name: Company name
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.
- Inactive Products
  - Comparative Analysis
- Nephrotic syndrome Key Companies
- Nephrotic syndrome Key Products
- Nephrotic syndrome- Unmet Needs



Nephrotic syndrome- Market Drivers and Barriers  
Nephrotic syndrome- Future Perspectives and Conclusion  
Nephrotic syndrome Analyst Views  
Nephrotic syndrome Key Companies  
Appendix  
Introduction  
Executive Summary  
Nephrotic syndrome: Overview  
    Causes  
    Mechanism of Action  
    Signs and Symptoms  
    Diagnosis  
    Disease Management  
Pipeline Therapeutics  
    Comparative Analysis  
Therapeutic Assessment  
    Assessment by Product Type  
    Assessment by Stage and Product Type  
    Assessment by Route of Administration  
    Assessment by Stage and Route of Administration  
    Assessment by Molecule Type  
    Assessment by Stage and Molecule Type  
Nephrotic syndrome – DelveInsight's Analytical Perspective  
In-depth Commercial Assessment  
    Nephrotic syndrome companies' collaborations, Licensing, Acquisition -Deal Value  
Trends  
Nephrotic syndrome Collaboration Deals  
    Company-Company Collaborations (Licensing / Partnering) Analysis  
    Company-University Collaborations (Licensing / Partnering) Analysis  
Mid Stage Products (Phase II)  
    Comparative Analysis  
Belimumab: GlaxoSmithKline  
    Product Description  
    Research and Development  
    Product Development Activities  
Drug profiles in the detailed report.  
Early Stage Products (Phase I)  
    Comparative Analysis  
Drug name: Company name

Product Description  
Research and Development  
Product Development Activities  
Drug profiles in the detailed report.  
Inactive Products  
Comparative Analysis  
Nephrotic syndrome Key Companies  
Nephrotic syndrome Key Products  
Nephrotic syndrome- Unmet Needs  
Nephrotic syndrome- Market Drivers and Barriers  
Nephrotic syndrome- Future Perspectives and Conclusion  
Nephrotic syndrome Analyst Views  
Nephrotic syndrome Key Companies  
Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Nephrotic syndrome

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Nephrotic syndrome
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Nephrotic syndrome - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/N26B8B72F56BEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N26B8B72F56BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970